Introduction
Hepatic fibrosis (HF) represents a scarring response to either acute or chronic cellular injury. Following acute liver injury, parenchymal cells regenerate to successfully preserve hepatocellular mass and function. This acute process is associated with an inflammatory and fibrogenic response but limited deposition of extracellular matrix (ECM). In contrast, prolonged liver injury leads to sustained production of growth factors, proteolytic enzymes, angiogenic factors and fibrogenic cytokines. These events culminate in the accumulation of ECM, forming septa that coalesce into broad bands of scar tissue that encircle nodules of hepatocytes and lead to altered microvascular structure 1 . This late stage of fibrosis, termed cirrhosis, ultimately impairs liver function and leads to portal hypertension and its complications. Participation of various cell types, interlinked cellular events and large number of mediator molecules make the fibrotic process enormously complex and dynamic 2 . For decades, HF was seen as an irreversible disease that progresses to cirrhosis, with a greater risk for developing hepatocellular carcinoma (HCC) and liver failure. This meant the only potential treatment for HF once it had progressed to cirrhosis was transplantation. Research over the past 30 years has yielded increasing insight into the cellular and molecular mechanisms of this disease, uncovering an orchestrated pathophysiology and identifying the hepatic stellate cell (HSC) as the central cell type in fibrogenesis 3 . Most importantly, this revealed the potential reversibility of this disease and the discovery of potential therapeutic targets 4 . HF research has gained global attention because of its close relationship with disease progression triggered by hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, which leads to end-stage liver cirrhosis and ultimately to HCC 5 . Currently, nearly 3 billion and 180 million people have been exposed to HBV and HCV, respectively 6, 7 . Epidemiological studies have shown that in China, HBV infection is the major cause of HF, whereas in the United States, Europe and Japan, HCV infection, alcohol abuse and non-alcoholic steatohepatitis (NASH) are the main causes 8, 9 . In the sub-Saharan African region, Schistosoma mansoni infection is reported to be the major cause of HF, resulting in almost 0.3 million deaths annually 10 . In spite of the high incidence of HF worldwide, no generally accepted antifibrogenic therapy is available. Moreover, the research and development of new drugs with anti-HF activity has been an international puzzle.
In recent years, considerable achievements have been made in China in research of the aetiopathogenesis, diagnosis and especially the treatment of HF. Based on the clinical practice of traditional Chinese medicine (TCM), some effective TCM formulae have been developed and used for the treatment of HF. However, the components in these formulae are complicated. The anti-HF drugs with distinct components, significant effects and definite pharmacological mechanisms but without side or toxic effects are still lacking. Thus, it is a significant trend to find out active anti-HF components in TCM, which may be a consider-also prolongs the survival of activated HSC by reducing their apoptosis, which is opposite to its effect on epithelial cells, such as hepatocytes 14 . PDGF is the most potent cytokine that induces proliferation of HSC in vitro, and probably it plays a major role in the activation and proliferation of HSC in vivo 15 . The activated HSCs express more PDGF receptors and release PDGF too. The PDGF and TGF-β secreted by HSCs create an autocrine loop, which is an important mechanism for perpetuating HSC activation 16 . Moreover, liver injury induces cross-talk between hepatocytes, Kupffer cells, inflammatory cells and HSC, which greatly contribute to liver fibrogenesis. In addition, changes in the microenvironment of the HSC also contribute to their activation. In the normal situation, HSC are quiescent and produce small amounts of ECM components, such as laminin and collagen type IV for the formation of basement membrane 17 . When they are exposed to soluble factors from damaged hepatocytes and from activated Kupffer cells, HSCs will lose their lipid content (retinyl palmitate), undergo upregulation of cytoskeletal protein expression such as α-smooth muscle actin (α-SMA) and desmin and undergo morphological transition to myofibroblast-like cells. Furthermore, activated HSCs, in turn, upregulate adhesion molecules and secrete proinflammatory cytokines (IL-6, IL-8 and monocyte chemoattractant protein-1), further accelerating recruitment of inflammatory cells into the injured liver. On the other hand, activated HSCs change their secretion profile of ECM components, releasing more interstitial collagens instead of components of the basement membranes. Accumulated interstitial collagens are regulatory factors for the prolonged production of ECM by HSCs and for other behaviours of the cells 18 . The importance of the ECM as an active, signalling component of fibrogenesis is well accepted now. . TGF-β not only induces activation of HSC, enhances expression of PDGF receptors on the cells and enhances the autocrine expression of TGF-β by the cells but able shortcut for the development of anti-HF drugs 11 . The present review covers recent information on the general mechanisms of HF and the current status of TCM research on the anti-HF.
Activation of HSC

Molecular mechanisms of hepatic fibrogenesis
HF is an outcome of many chronic liver diseases, such as chronic infection by HBV, HCV and parasite Schistosoma; chronic alcoholism or exposure to certain drugs and toxins; infections; NASH and inherited metabolic diseases like hematochromatosis, Wilson's disease, α-1 antitrypsin deficiency, autoimmune diseases such as primary biliary cirrhosis, ischemia and autoimmune hepatitis eration of liver parenchymal cells. Senescence of HSCs depends on the length of telomeres, a non-coding region at the end of chromosomes, which shortens with each division and, once critical length is reached, prevents HSC from further cellular division 34 . In addition, activated HSCs produce TIMP, which inhibits collagendegrading matrix metalloproteinases (MMPs) and shifts the balance between ECM synthesis and degradation towards ECM synthesis 31 , which is considered as the primary mechanism of fibrosis resolution. Therefore, apoptosis of HSC eliminates not only the major source of collagen but the major source of TIMP-1 and leads to increased activity of MMP interstitial collagenases and subsequent degradation of ECM 35, 36 .
Therapeutic targets of traditional
Chinese medicine on HF TCM has recently attracted the attention of practitioners of western medicine. The principles underlying TCM were established over thousands of years and are based on clinical experience and practice. So far, no satisfactory treatment protocol with western drugs is available for HF because of their severe side effects. However, with the research of the TCM in recent years, we have obtained promising results, and a number of Chinese herbals have been found to reverse the progression of HF without obvious side effects. Chinese herbal recipes display unique features in the treatment of acute and chronic liver injury. Studies have shown that TCM can inhibit the deposition of collagen fibres 37 and promote the reversion of fibrosis, which was confirmed by experimental evidence that Sal-B and salvianolic acid A (Sal-A) extracted from Radix Salviae Miltiorrhizae, matrine (M) and oxymatrine (OM) from Seed Sophorae Alopercuroidei or Radix Sophorae Flavescentis, Radix Angelicae Sinensis, Radix Astragali seu Hedysari, Radix Paeoniae TNF-α. In addition, Kupffer cells, which can be regarded as important 'coefficients', help maintain the kinetic equilibrium of HF and mediate the feedback mechanism of some biological messages during the progression of HF. HSCs have both paracrine and autocrine functions, the activation of which can be triggered via a reaction cascade of cytokines and biochemical factors 26, 27 . Two major changes occur after the activation of HSCs, that is, proliferation and phenotypic transition 28 . As reviewed in the activation of HSCs, PDGF and TGF-β play an important role in the proliferation and transformation of HSCs 29 . The key role of PDGF, a most effective mitogen during the synthesis of HSC DNA 30 , is to convert HSC from G0 to G1 and S phases, whereas TGF-β promotes the synthesis of collagen and tissue inhibitors of matrix metalloproteinases (TIMPs) in activated HSCs 31 . Moreover, PDGF and TGF-β can interact with each other. PDGF is capable of inducing HSCs to express and secrete PDGF receptors. PDGF and TGF-β can also interact with TNF-α 32 , leading to the formation of cytokine network with HSCs at the crucial centre.
Activated HSC apoptosis
Recently, activated HSC apoptosis is regarded as a key factor in regression of HF. Activated HSCs are more susceptible to apoptosis and can undergo spontaneous cell death or death receptor-mediated cell death caused by serum deprivation or cytokine signalling. In response to reduced fibrogenic signals or antiviral drug therapy, HSCs increase the expression of Fas receptor or TNF receptor 1 and their ligands and undergo a caspase 8/caspase 3-dependent apoptosis. Alternatively, overexpression of proapoptotic proteins such as p53, Bax and Bcl-2 leads to caspase 9-mediated programmed cell death 33 . Furthermore, senescence of HSC may be an important mechanism to slow proliferation and favour the regen- 12, 19, 20 . . Substantial evidence has demonstrated that these ROS are active inducers of HSC activation in vitro 22 and may also play a pivotal role in vivo 23 . Antioxidants, such as vitamin E, S-adenosyl-l-methionine (SAMe) and polyenylphosphatidylcholine, display protective effects for the liver from injury induced by hepatotoxins, as well as block the progress of the fibrogenesis 21, 24 . Recently, the study of De Bleser et al. showed that treatment of HSC with TGF-β induced the production of H 2 O 2 in the cells, whereas treatment of the cells with catalase, a scavenger of H 2 O 2 , decreased the production of TGF-β by the cells 25 . Thus, antioxidants are useful in both the prevention of liver injury and the attenuation of fibrogenesis. Furthermore, many agents such as silymarin, salvianolic acid B (Sal-B), colchicine and Chinese herbal recipes (Xiao Chaihu Tang, Recipe 861) exhibit their antifibrotic effects via this mechanism.
Inflammatory signalling
HSCs, which are reviewed above, have emerged as central modulators of hepatic inflammation and immunity, and not just passive targets of inflammatory cytokines. In particular, a growing list of chemokines and their cognate receptors serve the dual function of provoking further fibrogenesis and interacting with inflammatory cells to modify the immune response during injury
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Activated Kupffer cells release a variety of cytokines closely related to HF such as TGF-α and -β, PDGF and systematically investigated and used in clinics so far. Previous studies have shown that Sal-B could significantly prevent and treat HF induced by carbon tetrachloride in animal experiments 44 . The mechanisms of Sal-B on anti-HF were as follows: 45, 46 anti-lipid peroxidation; inhibiting expressions of TGF-β 1 and TGF-β receptor protein; inhibiting Smad2 phosphorylation and downregulating TGF-β1/ Smads signal conduction in HSCs and inhibiting intracellular extracellular signal-regulated kinase signalling conduction induced by TGF-β1. On the other hand, the results of the liver biopsy in 60 patients before and after a 6-month treatment suggested that Sal-B could effectively reverse HF in patients with chronic hepatitis B, with a reverse rate of 36.6% by histological examination, which is superior to interferon-γ Other experiments showed similar results in a model of HF induced by a choline-deficient diet 42 . Extensive clinical use suggested that TJ-9 prevented the development of HCC in patients with HCV infection 43 . Recipe 861, which consists of 10 Chinese herbs, has been shown to reduce mRNA expression of pro-collagens I, III, V and TGF-β in the liver of animal models and in cultured HSCs to increase the production of interstitial collagenases (MMP-1) and to suppress TIMP-1 synthesis in HSC. Liver biopsies showed that the fibrosis was reduced or had completely disappeared in three-quarters of patients with hepatitis B after 6 Some of them were even found to be able to 'reverse' the fibrotic liver to a nearly normal histology in patients with HBV infection 38 , and no serious side effects were observed. Thus, the use of TCM suggests a bright future and a new approach in the treatment of liver disease (Figure 2) .
The Chinese herbal medicine Xiao Chaihu decoction (TJ-9) is an officially approved prescription drug in Japan and is presently the most commonly administered drug in Japan to outpatients with chronic liver disease, especially those with chronic hepatitis 39 and liver cirrhosis 40 .
In vivo experiments show that TJ-9 increased liver retinoid levels and decreased the total collagen content and the number of α-SMA positive cells 41 . In vitro experiments show that TJ-9 is a strong antioxidative agent that inhibited both lipid peroxidation in hepatocytes and oxidative stress-induced HSC activation. Furthermore, TJ-9 also displays radical scavenger activity. The main components in TJ-9 that exert antioxidative treatment depends on a single active herbal component. Therefore, with the guidance of the wholism of the TCM, researches of anti-HF components should return to the pharmacological effect with multipathway and multitarget approach. The TCM formulae will be upgraded to the active component formulae after the epistemological circulation of 'herbal formula-effective component-component formula', which makes the TCM formula upgrade to the level of effective component formula 11 . At that time, the novel Chinese medicine formula for anti-HF, based on the theory of TCM and composed of active compounds with significant curative effect, definite material substructure, high stability and quality control, will be available. That is, probably a research trend on anti-HF with integrated Chinese and western medicine, and it deserves more attention.
Problems, however, do exist in TCMs, in the standardisation and purification methodology. Currently, no standardised criteria are available to compensate for the geographical variation in the content of effective components of drugs, and the methods of harvest and refinement are also controversial. In addition, most of the researches on active anti-HF components were pharmacodynamic tests in animals, and there were not many detailed investigations, which is important to find a new active component. However, the further optional mechanism researches on the components available are also valuable. The active components should be further investigated to reveal the effective targets and to be tested in standardisation and strict doubleblind, multicentre studies.
Conclusion
From what we reviewed above, it is expected that the favourable prospect of anti-HF Chinese herbal components will be achieved. And the researches on active components provide considerable scientific nese herbal medicine, the effective component formula investigations deserve more attention and probably prompt a potential researching direction.
Discussion
The author has referenced some of its own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) , and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies. HF has been investigated actively since HSCs were identified by Dr Scott Friedman in 1985 3 as the principal collagen-producing cells in the liver. The field of HF is flourishing, thanks to the continued experimental advances complemented by exciting progress in the treatment of chronic liver disease
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. Recently, there is considerable research going on to develop antifibrotic strategies that are applicable to HF. Such an approach is attractive because it is aimed at the final common pathological pathway of chronic liver disease, regardless of the aetiology. Activation of resident HSCs into proliferative, contractile and fibrogenic cells in liver injury remains a dominant theme driving the field. Based on the complex pathogenesis of HF, the drug treatment of HF focused on a single target seems unfeasible. Thus, approaches that act to inhibit HSC activation and proliferation and matrix production at multiple locations may be more effective than targeting a single step of the fibrogenic cascade. The agents that display multiple actions include antioxidants, such as SAMe, silymarin and TCMs (Xiao Chaihu decoction, Recipe 861).
Moreover, the wholism, the important characteristic and superiority of TCM, may be ignored, while the Flavescentis ait. Recently, OM has been used in the treatment of chronic liver disease and has a significant effect on the inhibition of HF. The discovered mechanism of actions of OM on anti-HF included inhibiting hepatic expressions of Smad4 protein and upregulating Smad7 protein in rats; inhibiting HSC activation and hepatic collagen synthesis and inhibiting Kupffer cell activation and paracrine to restrain HSC proliferation [48] [49] [50] . Furthermore, liver biopsy before and after treatment in 49 patients suggested that OM could reverse HF in chronic viral hepatitis patients, with the histopathological effective rate of 48%
51
. Glycyrrhizin is extracted from Radix Glycyrrhizae. The study by Wang et al. showed that it has the inhibitory effect on NF-kB-binding activity in CCl 4 -plus ethanol-induced liver cirrhosis in rats, as well as on the degree of the liver fibrosis
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. Therefore, its effects are also thought to be secondary to its antioxidative properties. It has also been used for the treatment of viral hepatitis B because it was found that glycyrrhizin and related compounds could inhibit the release of hepatitis B surface antigen from infected hepatocytes 53 . In addition to the above description, other recipes have also been shown to be effective in the prevention of HF. Recent experimental studies and clinical trials suggest that Chinese herbal medicines may play a significant role in the therapy of HF. They appear to function at multiple phases of the process of hepatic fibrogenesis. Many groups are presently interested in analysing the effectiveness of these agents. In addition, antifibrotic therapy targets at the inhibition of HSC proliferation, cytokine activity and ECM degradation and also the apoptosis of HSC was another interest of study in recent years [54] [55] [56] . Moreover, we considered that, in view of the complex pathogenesis and the multipathway and multitarget superiority of Chi-evidence for studying Chinese medicine compounds on antifibrosis and elucidating the material substructure of anti-HF Chinese medicine formulae. It is anticipated that more findings will be discovered through further researches, and ultimately, it is helpful to the patients.
Furthermore, broadening our horizons by critically exploring age-old remedies may still yield important information. We should not overlook these opportunities in our zeal to embrace technology-driven drug discovery. We believe that the incidence of HF or hepatic cirrhosis can be lowered with its prognosis improved, when more effort is made in research of the complex mechanism of fibrosis and cirrhosis and their molecular biology, serological diagnosis, complications in relation to hepatic cirrhosis, application of integrated Chinese and western medicine and especially the study of the curative mechanism of Chinese herbs, their serological pharmacology and the extraction of effective components.
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